Replies to post #57951 on RespireRx Pharmaceuticals Inc (fka RSPI)

[bigtalan]

That is about the jist I have gotten also , the website was a low item on the list now it seems that people havent mentioned it being an issue. That I will throw the BS flag , the key part he said of what you wrote is he is very thin trying to do it all, keeping cost down for RSPI , but what is actually falling thru the cracks at some point if help is needed in fields he missing then bring the right people in IMO, yes a cost may occur or you award shares but you have to be ahead of the curve. Again I still question all the people that have contacts with BP and no support from anyone that is a mystery to me. A 0% loan for a stake down the road ect.. something IMO could come from some of the deep pocket friends. Time will tell. GLTA and thanks for your post

[Sparkify]

I doubt the officers of being paid at the moment; at least not in cash. Websites cost money to build and update. If they don't have the money, that's a reality. I would rather they focus on the grants and fundraising, at this point. Institutional investors aren't convinced by a website, so I agree with him that it's a low priority item today....especially when money is so tight. Good luck to us each and all.

[LTListener]

I suspect this post really highlights and touches upon the progress where they are at with KRM-ll-81.

NIH saw astounding potential as evidenced in preclinical modeling and provided the funds for IND enabling work.

One common purpose of IND enabling is scaled up and consistent manufacturing. This is a risk no doubt. Yet my cursory research tends to believe scaling up manufacturing can easily be overcome with this type of molecule similar to how you described your conversation, but it does take time. If they have initiated tox studies then that is suggestive. I think probably the bigger risk is there any sensitivities in performance between what looks like a "remarkable" candidate coming from lab manufacturing to what is needed for scaled up, cost effective manufacturing. I assume the goal is to closely match lab manufacturing to manufacturing at scale, but how close is sufficient and at what cost? As hyped up to the potential of KRM-ll-81, one must acknowledge the risk of failure exists in this IND enabling process.

But make no mistake, it passes this step and becomes ready for IND submission, capital money will flow swiftly towards getting this level of candidate into human trials. And probably by inference, no need to update shareholders and website because it would be logical that commitments will be in place once the IND is ready. My impression is the IND enabling process is all about de-risking the asset. At some point, money watching these developments is going to find a risk profile they like and hopefully help accelerate the development and get it across the goal line.

[Dyno89]

Well, so much for thinking we were going to get some type of meaningful progress update from them around June. 

[All City Baby]

I should have phrased the one part of my post better. I believe he said that "If you're one shareholder out of 100...", in order indicate I was in the minority of shareholders taking an issue with the website, although maybe not the only one. A minor distinction but I don't want to misquote people.